-+ 0.00%
-+ 0.00%
-+ 0.00%

ADAGENE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1 STUDY OF MUZASTOTUG IN COMBINATION WITH INCYTE’S INCA33890 IN PATIENTS WITH MICROSATELLITE STABLE COLORECTAL CANCER

Reuters·10/28/2026 11:00:05

Please log in to view news